Literature DB >> 12822459

[Two cases of vesical nephrogenic adenoma].

Hiroyuki Tsurukawa1, Hideki Komura, Hiroshi Sasaki, Hiromichi Iuchi, Masayuki Tokumitsu, Yuji Saga, Satoshi Yamaguchi, Hiroshi Hashimoto, Sunao Yachiku.   

Abstract

Case 1: A 52-year-old man receiving regular treatment for quadriplegia due to Friedreich disease visited our hospital with the chief complaint of macroscopic hematuria. He had undergone cystostomy 12 years ago due to neurogenic bladder. The computed tomography and cystoscopic examination revealed a bladder tumor with a few bladder stones. Transurethral resection of bladder tumor (TUR-Bt) was performed after bladder stone removal in May 2000. The pathological diagnosis showed nephrogenic adenoma. Case 2: A 54-year-old man had been treated with bladder tumor by TUR-Bt in Nov. 1995. The pathological diagnosis showed transitional cell carcinoma, G3, pT2 and intravesical instillation therapy using THP was performed. The bladder tumor had recurred twice and the instillation therapy had been exchanged to BCG since Nov. 1997. A small bladder tumor was observed in Jan. 2001, and from the biopsy specimen it was diagnosed as nephrogenic adenoma. Forty-six cases of urothelial nephrogenic adenoma including our cases have been reported in Japan. Chronic stimulation such as bladder stone and infection is thought to induce nephrogenic adenoma. BCG instillation therapy is believed to be an initiation factors for nephrogenic adenoma.

Entities:  

Mesh:

Year:  2003        PMID: 12822459

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

Review 1.  Nephrogenic adenoma of the urinary bladder.

Authors:  Konstantinos Zougkas; Marinos Kalafatis; Panagiotis Kalafatis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

2.  Nephrogenic adenoma of the urinary bladder.

Authors:  Konstantinos Zougkas; Marinos Kalafatis; Panagiotis Kalafatis
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.266

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.